Trial Profile
A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 28 Jun 2016 Results of cohort of a patients with HCV genotype 4 subtypes (n=44) published in the Hepatology
- 17 Apr 2016 Results of an integrated analysis from five trials (n=236) presented at The International Liver Congress™ 2016
- 13 Jan 2016 According to ClinicalTrials.gov record,Number of treatment arms changed from 4 to 2.